Abstract 1170: An off-the-shelf vaccine activates mutant KRAS-specific T cells in patients with resected pancreatic cancer

作者
Amanda L. Huff,Alexander A. Girgis,Saurav Daniel Haldar,Emily F. Davis-Marcisak,Thatcher Ross Heumann,Gabriella Longway,Lalitya Andaloori,Alexei Hernandez,Maximilian F. Konig,Brian J. Mog,Ludmila Danilova,Luciane Tsukamoto Kagohara,Julie M. Nauroth,Amy Morck Thomas,Elana Judith Fertig,Won Jin Ho,Elizabeth M. Jaffee,Nilofer Saba Azad,Neeha Zaidi
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 1170-1170
标识
DOI:10.1158/1538-7445.am2024-1170
摘要

Abstract Background: Oncogenic mutations in KRAS (mKRAS) are expressed in up to 90% of pancreatic ductal adenocarcinomas (PDAC) therefore representing a promising immunotherapeutic target. We developed a pooled mKRAS peptide vaccine targeting the 6 most common mutations in PDAC: G12V, G12A, G12C, G12R, G12D, or G13D (NCT04117087). In a phase I study, we evaluated mKRAS-specific T cell responses raised by the vaccine when given in combination with immune checkpoint inhibitors to PDAC patients following resection and adjuvant chemotherapy. Materials and Methods: Patients received the pooled mKRAS peptide vaccine (0.3mg/peptide and 0.5mg poly-ICLC weekly for 4 doses in combination with ipilimumab and nivolumab followed by boosters every 8 weeks with nivolumab. To detect vaccine-induced mKRAS-specific T cells, pre- and post-vaccine peripheral blood mononuclear cells (PBMCs) were restimulated with control or individual mKRAS peptides and IFNγ release was measured by ELISPOT. mKRAS-specific T cell activation, proliferation, memory, and exhaustion profiles were assessed by CyTOF and cytokine secretion was determined by ELISA. For a subset of patients, mKRAS-specific T cells were expanded in vitro and T cell receptor (TCR) β chain sequencing and scRNA/TCRseq were used to identify the KRAS mutation-specific TCR repertoires and define their phenotypes in circulation. Results: mKRAS-specific T cells were detected by IFNγ ELISPOT post-vaccination for all patients, although magnitude and mutation-specific responses varied between patients. CyTOF analysis identified mKRAS-specific Th1 CD4+ central memory (cm, CCR7+IFNγ+) and effector memory (em, CCR7-IFNγ +IL2+ TNFɑ+) responses as well as CD8+ effector (eff, CD137+GZMBhiKi67hi) and effector memory (CCR7-CD137+GZMB+) responses. mKRAS-specific T cells were also detectable in the extended booster phase of treatment (>1 year post initial vaccination). In vitro expanded mKRAS-specific T cells mapped to CD4+ Tcm/em and CD8+ Tem populations within single cell datasets of unstimulated PBMCs collected post-vaccine. 5-25% of the mKRAS-specific T cells significantly expanded to more than one mKRAS antigen suggesting potential cross-reactive T cell clonotypes. In addition, shared public mKRAS-specific T cell clonotypes were identified across patients. Conclusions: This study demonstrates mKRAS vaccine induction of de novo, high quality mKRAS-specific polyfunctional CD4+ and CD8+ T cells. mKRAS-specific TCR analysis identified shared public TCRs across vaccinated patients that have important implications for future “off the shelf” adoptive therapy approaches. Ongoing studies are aimed to validate antigen specificity and map HLA-restriction of mKRAS-specific T cells. Overall, this study demonstrates a positive immunogenic signal of this pooled mutant KRAS vaccine that may be amenable for interception vaccination strategies against PDAC. Citation Format: Amanda L. Huff, Alex Girgis, Saurav D. Haldar, Emily Davis-Marcisak, Thatcher Heumann, Gabriella Longway, Lalitya Andaloori, Alexei Hernandez, Maximilian F. Konig, Brian Mog, Ludmila Danilova, Luciane T. Kagohara, Julie M. Nauroth, Amy M. Thomas, Elana J. Fertig, Won Jin Ho, Elizabeth M. Jaffee, Nilofer Azad, Neeha Zaidi. An off-the-shelf vaccine activates mutant KRAS-specific T cells in patients with resected pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1170.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无极微光的应助被李萌采纳,获得20
刚刚
ZRT完成签到,获得积分10
2秒前
尊敬的白风完成签到,获得积分10
2秒前
2秒前
Rolly发布了新的文献求助10
3秒前
3秒前
笑点低人英完成签到,获得积分10
3秒前
烟花的应助被zkyyy采纳,获得10
4秒前
4秒前
传奇3的应助被zkyyy采纳,获得10
4秒前
诚心的傲旋完成签到,获得积分10
4秒前
钟梓袄发布了新的文献求助10
4秒前
5秒前
Peggy完成签到,获得积分10
5秒前
脑洞疼的应助被尊敬的白风采纳,获得10
5秒前
5秒前
小二郎的应助被顺利毕业采纳,获得10
6秒前
TIX完成签到 ,获得积分10
6秒前
6秒前
小马甲的应助被英勇冰淇淋采纳,获得10
6秒前
6秒前
6秒前
于呆呆完成签到,获得积分10
6秒前
7秒前
Chansue发布了新的文献求助10
7秒前
han发布了新的文献求助10
8秒前
hhh完成签到,获得积分10
8秒前
chi发布了新的文献求助10
8秒前
8秒前
8秒前
9秒前
忧郁虔完成签到 ,获得积分10
9秒前
小恶魔发布了新的文献求助10
9秒前
9秒前
qtfy发布了新的文献求助10
10秒前
10秒前
baijie发布了新的文献求助10
11秒前
无花果的应助被cbk12345采纳,获得10
11秒前
爆米花的应助被跳跃采纳,获得10
12秒前
Famiglistmo发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124